Clovis Oncology Files For IPO

Boulder-based Clovis Oncology, a developer of anti-cancer drugs, has filed for an IPO, saying that it is looking to raised up to $149.5M on the public markets. The firm has applied to list on the NASDAQ GLobal Market as CLVS. The firm's IPO is being underwritten by J.P. Morgan, Credit Suisse, and Leerink Swan. Clovis Oncology is venture backed by : Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth Bioventures, Frazier Healthcare Ventures, Pfizer, and ProQuest Investments.